Abstract
Background Accelerometer-based digital measures offer a scalable and low-burden means of quantifying physical function, but existing processing algorithms may not quantify pathological gait correctly. In people living with amyotrophic lateral sclerosis (ALS), where gait patterns are slow, variable, and asymmetric, validated tools to quantify mobility are urgently needed.
Methods We proposed a step-counting algorithm designed for ankle-worn accelerometers that leverage wavelet-based decomposition to quantify heel strikes under heterogeneous gait patterns. We validated this method using five datasets comprised of healthy individuals and those with ALS in controlled and semi-controlled activities, and we performed clinical validation in a free-living cohort of 305 people with ALS. We tested our method for accuracy in detecting steps and recognizing walking activity. Reference labels used for analytical validation were obtained from annotated studies or video-based ground truth. Step counting accuracy was assessed using Bland-Altman analysis while clinical validity was evaluated by comparing step counts to gross motor functioning on the ALS Functional Rating Scale – Revised (ALSFRS-R).
Results Walking recognition was robust across walking conditions and body types; sensitivity ranged from 0.94 to 0.98, and specificity exceeded 0.95 across all evaluated datasets. The mean step counting bias was minimal (e.g., 0.44 steps), and the 95% limits of agreement were narrow (LoA = [−5.90, 5.40]) relative to reference standards, including video-annotated ground truth. Clinical validation indicated substantial differences between groups with various levels of gait impairment, e.g., participants who reported “walks with assist” on the ALSFRS-R accumulated a mean of 1283 (95% CI: 1063, 1503) steps/day, while those reporting “normal” walking covered 3984 (95% CI: 3537, 4432) steps/day.
Conclusions Our study covered analytical and clinical validation of a step-counting method developed for ankle-worn accelerometers and demonstrated its applicability to pathological gait. The method provides accurate quantification of walking activity in controlled and free-living environments, supporting its use as a digital endpoint in ALS research.
Competing Interest Statement
MS has served as a paid consultant for Regeneron. KMB reports no competing interests. KTC reports no competing interests. NC reports no competing interests. SM reports no competing interests. AP reports no competing interests. FGV reports no competing interests. JDB has received research support from Biogen, MT Pharma of America, MT Pharma Holdings of America, Rapa Therapeutics. He has served as a paid consultant for MT Pharma of America and MT Pharma Holdings of America, Regeneron, Roon, and Alexion. He served as a paid member of a data and safety monitoring board for Sanofi. He acts as an unpaid scientific advisor for the non-profit organizations ALS One and Everything ALS.
Funding Statement
The PFALS study was an investigator-initiated study conducted with funding from Biogen.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol for ARC was approved by the Institutional Review Board (ADVARRA Center for IRB Intelligence). The study protocol for PFALS was approved by the Institutional Review Board of Massachusetts General Brigham (IRB# 2020P000546). The dataset (deidentified subject data) consisted of raw sub-second level accelerometry measurements described by subject demographics only, as summarized in Table 1.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The PFALS and ARC datasets may be shared upon request and after review and approval by the owners of the data. Shared data will consider deidentified summary statistics used for analytical analysis. Related correspondence should be sent to jdberry{at}mgh.harvard.edu (PFALS) and fvieira{at}als.net (ARC).
6. List of abbreviations
- ALSFRS-R
- ALS Functional Rating Scale-Revised.
- ARC
- ALS Research Collaborative dataset.
- BMI
- Body mass index.
- CI
- confidence intervals.
- CWT
- continuous wavelet transform.
- DaLiAc
- Daily Life Activities dataset.
- DHT
- Digital Health Technology.
- GT
- ground truth.
- IWSCD
- Identification of Walking, Stair Climbing, and Driving using Wearable Accelerometers dataset.
- LoA
- levels of agreement.
- PedEval
- Pedometer Evaluation Project dataset.
- PFALS
- Endurance Tasks to Measure Performance Fatigue in ALS dataset.
- SD
- standard deviation.
- SPADES
- Human Physical Activity dataset.
